Registry of patients with eosinophilia affecting the respiratory system

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a registry of patients suffering from eosinophilic lung diseases, such as eosinophilic asthma and eosinophilic granulomatosis with polyangiitis. It seeks to better understand the relationship between blood eosinophil counts and respiratory manifestations, as well as the potential for organ damage in conditions like hypereosinophilic syndrome. By characterizing different subtypes of eosinophils, the study hopes to clarify the clinical relevance of eosinophilia and improve therapeutic approaches. The study does not involve any interventions but focuses on collecting and analyzing patient data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* age ≥ 18 years
* documented blood eosinophilia ≥ 300 cells/µl
* present tissue damage of the respiratory tract caused by eosinophils

Exclusion Criteria:

* age \< 18 years
* pregnancy
* dementia
* incapacitated patients

Where it's running

• University Clinic for Internal Medicine II
  Innsbruck, Austria Recruiting

Study contacts

• Study coordinator: Ivan Tancevski, MD
• Email: ivan.tancevski@i-med.ac.at
• Phone: +43 50504 81602

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Machine learning to distinguish EGPA from HES

  This project will test whether machine learning applied to clinical, lab, and instrument data can help tell EGPA apart from HES and predict how patients respond to treatment.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia · NCT07275190

• Oral KT-621 for adults with moderate to severe eosinophilic asthma

  This study will test whether an oral medicine called KT-621 can help adults with uncontrolled moderate to severe eosinophilic asthma and is safe and tolerable.

  Recruiting at 81 sites Phase 2 Kymera Therapeutics, Inc. · Lancaster, California and 80 other locations · NCT07323654

• Investigating the Role of Nasal Microbiome in Eosinophilic Granulomatosis with Polyangiitis

  This study is trying to see how the bacteria in the nose affect the immune system in people with Eosinophilic Granulomatosis with Polyangiitis and related conditions, and whether a new treatment can change that.

  Recruiting University Medical Center Groningen · Groningen · NCT06298448

• Benralizumab in EGPA: real-world effectiveness and safety

  This is a real-world study checking how well and safely benralizumab works for adults with eosinophilic granulomatosis with polyangiitis (EGPA).

  Recruiting European EGPA Study Group · Florence, Italy · NCT07815886

• Continued benralizumab for participants who completed a prior benralizumab study

  This trial tests continuing benralizumab in people who benefited from it in a previous study, to see if long-term treatment is safe and tolerable.

  Recruiting at 20 sites Phase 3 AstraZeneca · Aurora, Colorado and 45 other locations · NCT07444567

• Investigating benralizumab for children with eosinophilic diseases

  This study is testing if a medication called benralizumab can help children aged 6 to under 18 with eosinophilic granulomatosis with polyangiitis feel better and stay healthy over a year of treatment.

  Recruiting at 13 sites Phase 3 AstraZeneca · Aurora, Colorado and 14 other locations · NCT06512883

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.